2022
Clinical trials in multiple sclerosis: past, present, and future
Manouchehri N, Shirani A, Salinas VH, Tardo L, Hussain RZ, Pitt D, Stuve O. Clinical trials in multiple sclerosis: past, present, and future. Neurologia I Neurochirurgia Polska 2022, 56: 228-235. PMID: 35712986, DOI: 10.5603/pjnns.a2022.0041.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesMultiple sclerosisClinical trialsManagement of MSEffective disease-modifying therapiesDisability Assessment ScaleDisease-specific interventionsDisease diagnostic criteriaBurden of diseaseClinical trial developmentDisease-specific biomarkersMS pathophysiologyDiagnostic criteriaClinical practiceTrial developmentAssessment ScaleSclerosisTrialsPatientsNeuroimmunologyPathophysiologyTherapyDiseaseDiagnosisContinued progressEfficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
Manouchehri N, Salinas VH, Yeganeh N, Pitt D, Hussain RZ, Stuve O. Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Frontiers In Neurology 2022, 13: 854390. PMID: 35432156, PMCID: PMC9009145, DOI: 10.3389/fneur.2022.854390.Peer-Reviewed Original ResearchProgressive multiple sclerosisSecondary progressive MSMultiple sclerosisImmune senescenceSecondary progressive multiple sclerosisDifferent MS phenotypesDisease-Modifying TherapiesSuccessful clinical managementAge-related factorsAdvent of diseaseModifying therapiesProgressive MSRelapse frequencyClinical managementImmune responseDistinct pathogenesesImmune systemM phenotypeDisease transitionTherapyMain correlatesDisease phenotypePatientsRRMSSignal changes
2020
Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
Lucca LE, Lerner BA, Park C, DeBartolo D, Harnett B, Kumar VP, Ponath G, Raddassi K, Huttner A, Hafler DA, Pitt D. Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurology Neuroimmunology & Neuroinflammation 2020, 7: e712. PMID: 32269065, PMCID: PMC7188477, DOI: 10.1212/nxi.0000000000000712.Peer-Reviewed Original ResearchConceptsTumor-infiltrating T cellsT cellsPD-1/PD-L1Anti-TIGIT therapyExpression of CD226Expression of TIGITPostmortem CNS tissueLymphocytes of patientsFresh surgical resectionsLigand CD155TIGIT expressionSurgical resectionPD-1PD-L1CNS diseaseHealthy controlsHealthy donorsLymphocytic expressionImmune responseCNS tissueMS lesionsTIGITImmune pathwaysPatientsGlioblastoma multiforme
2016
Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping
Stüber C, Pitt D, Wang Y. Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping. International Journal Of Molecular Sciences 2016, 17: 100. PMID: 26784172, PMCID: PMC4730342, DOI: 10.3390/ijms17010100.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMagnetic resonance imagingBrain tissueQuantitative susceptibility mappingMS brain tissueAdvanced MRI methodsMS patientsChronic inflammationImmunohistochemical investigationBrain ironMyeloid cellsResonance imagingNon-invasive studyHistological studyRole of ironOxidative stressNoninvasive imagingSclerosisInflammationCellular distributionMRI methodsNeurodegenerationTissueImagingPatients
2015
Analysis of miRNA in Normal Appearing White Matter to Identify Altered CNS Pathways in Multiple Sclerosis
Guerau-de-Arellano M, Liu Y, Meisen WH, Pitt D, Racke MK, Lovett-Racke AE. Analysis of miRNA in Normal Appearing White Matter to Identify Altered CNS Pathways in Multiple Sclerosis. Journal Of Autoimmune Disorders 2015, 1 PMID: 26894232, PMCID: PMC4755487, DOI: 10.21767/2471-8153.100006.Peer-Reviewed Original ResearchCNS pathwaysMS patientsNormal Appearing White MatterBlood-brain barrierMultiple sclerosis susceptibilityPatients' CNSCNS inflammationMultiple sclerosisNeuroprotective mechanismsPost-transcriptional dysregulationControl subjectsUnderlying dysregulationImmune systemWhite matterCNSInflammationMiR-191Target predicationNAWMMiRNA profiling studiesPatientsMRNA analysisMAPK pathwayGenetic contributorsPathway analysis
2013
Quantitative Susceptibility Mapping of Multiple Sclerosis Lesions at Various Ages
Chen W, Gauthier SA, Gupta A, Comunale J, Liu T, Wang S, Pei M, Pitt D, Wang Y. Quantitative Susceptibility Mapping of Multiple Sclerosis Lesions at Various Ages. Radiology 2013, 271: 183-92. PMID: 24475808, PMCID: PMC4263629, DOI: 10.1148/radiol.13130353.Peer-Reviewed Original ResearchConceptsNormal-appearing white matterMS lesionsMultiple sclerosis lesionsEnhanced lesionsQuantitative susceptibility mappingMR examinationsSclerosis lesionsConventional magnetic resonance imagingMagnetic resonance imagingT2-weighted imagesMS patientsPathophysiologic featuresCerebrospinal fluidOnline supplemental materialWhite matterLesionsQSM imagesResonance imagingPatientsMR imagingThree-dimensional gradient-echo sequenceGradient echo sequenceMonthsBonferroni correctionAge
2012
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation
Bluestein KT, Pitt D, Sammet S, Zachariah CR, Nagaraj U, Knopp MV, Schmalbrock P. Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation. Magnetic Resonance Imaging 2012, 30: 907-915. PMID: 22578928, PMCID: PMC3402634, DOI: 10.1016/j.mri.2012.03.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlgorithmsCerebral CortexFemaleHumansImage EnhancementImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisNerve Fibers, MyelinatedReproducibility of ResultsSensitivity and SpecificitySubtraction TechniqueYoung Adult
2011
T1 and proton density at 7 T in patients with multiple sclerosis: an initial study
Bluestein KT, Pitt D, Knopp MV, Schmalbrock P. T1 and proton density at 7 T in patients with multiple sclerosis: an initial study. Magnetic Resonance Imaging 2011, 30: 19-25. PMID: 21937183, PMCID: PMC3375320, DOI: 10.1016/j.mri.2011.07.018.Peer-Reviewed Original ResearchConceptsCortical lesionsMultiple sclerosisWhite matterGray matterHealthy control subjectsWhite matter lesionsNormal-appearing tissueMS patientsMagnetic resonance sequencesMatter lesionsControl subjectsCerebrospinal fluidMS researchLesionsPatientsMR imagingUltrahigh-field MR imagingField MR imagingSclerosisProton densityResonance sequencesTissue responseTurbo fieldMagnetic resonanceInitial studyWhat happens when natalizumab therapy is stopped?
Schaaf SM, Pitt D, Racke MK. What happens when natalizumab therapy is stopped? Expert Review Of Neurotherapeutics 2011, 11: 1247-1250. PMID: 21864070, DOI: 10.1586/ern.11.109.Peer-Reviewed Original ResearchMS disease activityDisease activityActive diseaseNatalizumab cessationTreatment interruptionMultiple sclerosisBaseline levelsSimilar disease activityProgressive multifocal leukoencephalopathyNatalizumab exposureNatalizumab therapyNatalizumab treatmentMultifocal leukoencephalopathyMS patientsMRI measuresMS treatmentEvidence of reboundDiseaseElimination kineticsNatalizumabIntegrin antagonistsTreatmentPatientsCessationLeukoencephalopathy